OverviewSuggest Edit
Zymergen is a company that researches, develops and manufactures microbes for industrial application. It develops molecules for biomedical coatings and adhesives that can be used as surgical glues either inside the body or on the skin to close a wound or to protect against infection. The company also integrates artificial intelligence algorithms and robotic genomic to search the microbial genome, discover new materials, commercialize new products and improve existing bio-manufactured products.
| Type | Private | |
| Founded | 2013 | |
| HQ | Emeryville, CA, US | Map |
| Website | zymergen.com | |
| Employee Ratings | More | |
| Overall Culture | D- | More |
Recent NewsAll News
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zymergen, Annovis Bio, and Cassava Sciences and Encourages Investors to Contact the Firm
- ZY CLASS ACTION LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Zymergen, Inc.
- Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zymergen Inc. (ZY)
- HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Zymergen (ZY) Investors of Securities Class Action, Encourages Investors with Losses to Contact Firm’s Attorneys Now
Key People/Management at Zymergen
Josh Hoffman
Chief Executive Officer and Co-Founder, Director
Judy Gilbert
Chief People Officer
Jack Gold
Chief Marketing Officer
Mina Kim
Chief Legal Officer
Aaron Kimball
Chief Technology Officer
Zach Serber
Chief Science Officer and Co-Founder
Zymergen Office Locations
Zymergen has offices in Emeryville, Boise, Seattle and 千代田区
Emeryville, CA, US (HQ)
5980 Horton St #105
Boise, ID, US
12426 W Explorer Dr #250
Seattle, WA, US
1624 4th Ave #300
千代田区, JP
4F Otemachi First Square 1-5-1 Otemachi Chiyoda-ku
Zymergen Financials and Metrics
Summary Metrics
Founding Date | 2013 |
Zymergen total Funding | $876.1 m |
Zymergen latest funding size | $300 m |
Time since last funding | a year ago |
Zymergen investors | Goldman Sachs, Innovation Endeavors, True Ventures, SoftBank Capital, LLC, Threshold, Data Collective, AME Cloud Ventures, Two Sigma Ventures, Iconiq Capital, Baillie Gifford, Obvious Ventures, Prelude Ventures, Perceptive Advisors, Tao Capital Partners, Linden Mobile Ventures, Two Sigma Investments, Scifi VC, SoftBank Vision Fund, Data Collective DCVC, Hanwha Asset Management, Genoa Ventures, Baron Capital Group |
Zymergen's latest funding round in September 2020 was reported to be $300 m. In total, Zymergen has raised $876.1 m
Zymergen Revenue
Zymergen's revenue was reported to be $13.28 m in FY, 2020 which is a 13.8% decrease from the previous period.
| USD | |
|---|---|
Revenue (FY, 2020) | 13.3m |
Revenue growth (FY, 2019 - FY, 2020), % | (13.8%) |
Gross profit (FY, 2020) | (71.5m) |
Gross profit margin (FY, 2020), % | (538.5%) |
Net income (FY, 2020) | (262.2m) |
EBIT (FY, 2020) | 241.1m |
Cash (31-Dec-2020) | 210.2m |
| USD | FY, 2019 |
|---|---|
Revenue/Employee | 22.1k |
Debt/Equity | -0.2 x |
Debt/Assets | 0.4 x |
Financial Leverage | -0.5 x |
Zymergen Operating Metrics
Show all operating metricsZymergen Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| enEvolv | March 19, 2020 | |
| Radiant Genomics | January 08, 2018 |
Zymergen Revenue Breakdown
Zymergen revenue breakdown by geographic segment: 45.9% from United States of America, 35.7% from Asia and 18.4% from Europe
Zymergen Cybersecurity Score
Zymergen Online and Social Media Presence
9.19k Twitter followers
Zymergen has 9.19k Twitter Followers. The number of followers has decreased 0.2% month over month and increased 24.3% quarter over quarter
Zymergen's Trends
Zymergen Company Culture
Overall Culture
D-
56/100
CEO Rating
D-
56/100
Compensation
B
74/100
Zymergen News and Updates
September 23, 2021
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zymergen, Annovis Bio, and Cassava Sciences and Encourages Investors to Contact the Firm
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Zymergen Inc. (NASDAQ: ZY), Annovis Bio, Inc. (NYSE: ANVS), and Cassava Sciences,…
September 21, 2021
ZY CLASS ACTION LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Zymergen, Inc.
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securiti…
September 20, 2021
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zymergen Inc. (ZY)
BENSALEM, Pa., Sept. 20, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming October 4, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased or otherwise acquired Zymergen Inc. ("Zymergen" or the "Company")...
September 18, 2021
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Zymergen (ZY) Investors of Securities Class Action, Encourages Investors with Losses to Contact Firm’s Attorneys Now
SAN FRANCISCO, Sept. 18, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Zymergen Inc. (NASDAQ: ZY) investors with significant losses to submit your losses now.
September 17, 2021
ZY BREAKING ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Zymergen Inc. Investors with Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action – ZY
NEW YORK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zymergen Inc. (NASDAQ: ZY) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued…
September 16, 2021
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Oatly, Zymergen, Live Ventures, and SelectQuote and Encourages Investors to Contact the Firm
NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Oatly Group AB (NASDAQ: OTLY), Zymergen Inc. (NASDAQ: ZY), Live Ventures Incorpor…
Zymergen Blogs
July 30, 2021
The brave new world of protein structures and biofacturing
DeepMind has given us the 3-D structures of all human proteins. What does it mean for biofacturing? Here’s our take.
The post The brave new world of protein structures and biofacturing appeared first on Zymergen.
July 20, 2021
Does a billionaire space race really help humankind?
A handful of tourists are taking joy rides to space, but humanity’s true prospects for thriving on- and off-planet depend on unlocking the microbial factories all around us.
The post Does a billionaire space race really help humankind? appeared first on Zymergen.
July 09, 2021
The science of The Tomorrow War: The good, the bad, and the funny
When Hollywood tries its hand at biofacturing, sometimes science truth is better than science fiction
The post The science of The Tomorrow War: The good, the bad, and the funny appeared first on Zymergen.
June 25, 2021
Coding for microbes: A day in the life of a software engineer at Zymergen
A veteran of industry giants Ford and Apple, Aindrea Campbell’s manufacturing know-how will help bring biofacturing into the mainstream.
The post Coding for microbes: A day in the life of a software engineer at Zymergen appeared first on Zymergen.
June 24, 2021
The science of biofacturing: Josh Hoffman on This Week in Startups
CEO Josh Hoffman talks synthetic biology, biofacturing, and what’s next for Zymergen with This Week in Startups podcast host Jason Calacanis.
The post The science of biofacturing: Josh Hoffman on This Week in Startups appeared first on Zymergen.
June 22, 2021
Beyond the t-test: Using Bayesian modeling to separate signal from noise
A data science approach to finding commercially relevant titer improvements in fermentation
The post Beyond the t-test: Using Bayesian modeling to separate signal from noise appeared first on Zymergen.
Zymergen Frequently Asked Questions
When was Zymergen founded?
Zymergen was founded in 2013.
Who are Zymergen key executives?
Zymergen's key executives are Josh Hoffman, Judy Gilbert and Jack Gold.
How many employees does Zymergen have?
Zymergen has 833 employees.
What is Zymergen revenue?
Latest Zymergen annual revenue is $13.3 m.
What is Zymergen revenue per employee?
Latest Zymergen revenue per employee is $15.9 k.
Who are Zymergen competitors?
Competitors of Zymergen include Biodesix, Ischemia Care and Scailyte.
Where is Zymergen headquarters?
Zymergen headquarters is located at 5980 Horton St #105, Emeryville.
Where are Zymergen offices?
Zymergen has offices in Emeryville, Boise, Seattle and 千代田区.
How many offices does Zymergen have?
Zymergen has 5 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies